{
    "clinical_study": {
        "@rank": "139760", 
        "brief_summary": {
            "textblock": "To compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel\n      capsule (HGC) formulation, to 1 of 3 doses of saquinavir soft gel capsule (SGC) formulation\n      administered orally every 8 hours for 4 weeks."
        }, 
        "brief_title": "A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomly assigned to one of the four treatment groups as follows:\n\n      Group 1: 10 patients receive saquinavir HGC. Group 2: 10 patients receive saquinavir SGC.\n      Group 3: 30 patients receive saquinavir SGC at an intermediate dose. Group 4: 30 patients\n      receive saquinavir SGC at the highest study dose. Upon completion of the initial 4 weeks,\n      all patients may have the option to continue their originally-assigned therapy as\n      monotherapy unless significant drug toxicity intervenes. If the analysis of the initial 4\n      week data identifies an optimal dose of saquinavir SGC, patients may have the option to\n      change to this optimal dose in a treatment extension phase of the protocol. Patients in this\n      extension phase may choose to remain on monotherapy unless they experience significant drug\n      toxicity, their CD4 count or HIV-RNA levels return to baseline, until saquinavir is approved\n      by the FDA or study termination, whichever comes first.\n\n      NOTE: A washout >= 28 days is required for patients on antiretroviral therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  CD4 count of 100 to 500 cells/mm3.\n\n          -  Greater than 20,000 HIV-RNA copies/ml.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n        Prior treatment with protease inhibitors.\n\n        Required:\n\n          -  Less than 8 weeks prior antiretroviral treatment (For at least 25% of patients).\n\n          -  At least 8 weeks prior antiretroviral treatment (For at least 25% of patients)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "80", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002383", 
            "org_study_id": "229M", 
            "secondary_id": "NV15107"
        }, 
        "intervention": {
            "intervention_name": "Saquinavir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Saquinavir"
            ]
        }, 
        "keyword": [
            "Drug Administration Schedule", 
            "HIV Protease Inhibitors", 
            "Dosage Forms", 
            "Saquinavir", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Univ of Alabama at Birmingham / 1917 Rsch Cln"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94114"
                    }, 
                    "name": "Davis Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Mt Zion Hosp of UCSF / HIV Research Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherman Oaks", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91403"
                    }, 
                    "name": "Pacific Oaks Med Group / Research & Scientific Investiga"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Tulane Univ Med Ctr / Infectious Diseases Sect"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "New England Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64108"
                    }, 
                    "name": "Kansas City AIDS Research Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Harkness Pavilion"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97201"
                    }, 
                    "name": "Oregon Health Sciences Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "775550882"
                    }, 
                    "name": "Univ of Texas Med Branch / Virology Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized, Parallel, Open-Label Study Comparing Saquinavir (Hard Gelatin Formulation, 600 Mg Tid) to Saquinavir Soft Gelatin Formulation [(400 Mg, 800 Mg, 1200 Mg) Tid} x 4 Weeks in HIV Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "11364377", 
            "citation": "Cadman J. Roche brings new formulation of saquinavir to FDA. Food and Drug Administration. GMHC Treat Issues. 1997 Apr-May;11(4/5):8. No abstract available."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002383"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1997"
    }, 
    "geocoordinates": {
        "Davis Med Ctr": "37.775 -122.419", 
        "Harkness Pavilion": "40.714 -74.006", 
        "Kansas City AIDS Research Consortium": "39.1 -94.579", 
        "Mt Zion Hosp of UCSF / HIV Research Ctr": "37.775 -122.419", 
        "New England Med Ctr": "42.358 -71.06", 
        "Oregon Health Sciences Univ": "45.523 -122.676", 
        "Pacific Oaks Med Group / Research & Scientific Investiga": "34.149 -118.451", 
        "Tulane Univ Med Ctr / Infectious Diseases Sect": "29.951 -90.072", 
        "Univ of Alabama at Birmingham / 1917 Rsch Cln": "33.521 -86.802", 
        "Univ of Texas Med Branch / Virology Clinic": "29.301 -94.798"
    }
}